Evidence map›Paper›PMID 29748541›Full record

ArticleCell death & disease2018

RXRα provokes tumor suppression through p53/p21/p16 and PI3K-AKT signaling pathways during stem cell differentiation and in cancer cells.

Rui Zhang, Hui Li, Shuangshuang Zhang, Yujie Zhang, Nan Wang, Hao Zhou, Hongpeng He, Guang Hu, Tong-Cun Zhang, Wenjian Ma

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Homocysteine and thyroid diseases.Frontiers in endocrinology · 2025
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Rui ZhangCollege of Biotechnology, Tianjin University of Science and Technology, 300457, Tianjin, China.
Hui LiCollege of Biotechnology, Tianjin University of Science and Technology, 300457, Tianjin, China.
Shuangshuang ZhangCollege of Biotechnology, Tianjin University of Science and Technology, 300457, Tianjin, China.
Yujie ZhangCollege of Biotechnology, Tianjin University of Science and Technology, 300457, Tianjin, China.
Nan WangCollege of Biotechnology, Tianjin University of Science and Technology, 300457, Tianjin, China.
Hao ZhouCollege of Biotechnology, Tianjin University of Science and Technology, 300457, Tianjin, China.
Hongpeng HeCollege of Biotechnology, Tianjin University of Science and Technology, 300457, Tianjin, China.
Guang HuInstitute of Biology and Medicine, Wuhan University of Science and Technology, 430081, Wuhan, China.
Tong-Cun ZhangCollege of Biotechnology, Tianjin University of Science and Technology, 300457, Tianjin, China. zhangtongcun@wust.edu.cn.
Wenjian MaCollege of Biotechnology, Tianjin University of Science and Technology, 300457, Tianjin, China. ma_wj@tust.edu.cn.
Tianjin University of Science and Technology · CNWuhan University of Science and Technology · CNQilu University of Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The retinoid X receptor alpha (RXRα) is an important therapeutic target impacting diverse biological processes. Activation of RXRα is known to suppress cancer cell growth. However, the cellular mechanism has been elusive. In the present study, we addressed its role during stem cell differentiation and the underlying connections with carcinogenesis. RXRα was significantly upregulated following the differentiation of human mesenchymal stem cell (hMSC) toward the formation of endothelial cell (EC). However, overexpression of RXRα in hMSC provoked a senescence-like phenotype accompanied by the elevation of tumor suppressor p53, p21, and p16. Consistently, RXRα level was suppressed in cancer cells (~five times lower compared to differentiated hMSC), and its elevation could inhibit the proliferation, migration, and angiogenesis of cancer cells. We further demonstrated that these inhibitory effects were related to RXRα's interaction with estrogen receptor α (ERα) as well as EGF and ANGPTL3 through modulating PI3K/AKT signaling pathway by AKT and FAK phosphorylation. Moreover, RXRα inhibited glycolytic metabolism in cancer cells, which might be underlying its inhibition of differentiation and carcinogenic features. These data suggest that RXRα acts as a suppressor rather than a driving force during stem cell differentiation, and unbalanced RXRα can trigger multiple yet connected signaling pathways in preventing carcinogenesis.

Indexed as

Signal TransductionCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p21HumansHuman Umbilical Vein Endothelial CellsMCF-7 CellsNeoplasmsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRetinoid X Receptor alphaTumor Suppressor Protein p53CDKN1A protein, humanCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p21Phosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRetinoid X Receptor alphaRXRA protein, humanTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID29748541
PMCPMC5945609
OpenAlexW2799970137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.